Clinical trial · Interventional
Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma
NCT02892786CI-TRIAL-00125102CTCVADScompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The dissemination of individual tumor cells is a common phenomenon in solid cancers. Detection of tumor cells in peripheral blood circulating tumor cells (CTC) in nonmetastatic situation is of high prognostic significance. The objective of our study was to detect circulating tumor cells in two different method in patient with head and neck squamous cell carcinoma .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating Tumor Cells | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental
- interventionNames
- Other: Circulating Tumor Cells
Primary outcomes (1)
- measure
- Circulating tumor cells in peripheral blood during head and neck surgery
- timeFrame
- 7 days
- description
- The number of circulating tumor cells detected per milliliter of peripheral blood will be evaluated on the day before, the day of surgery and 7 days after the surgery.
Secondary outcomes (2)
- measure
- Comparison between RT-PCR and CellSearch™ method
- timeFrame
- 1 day
- description
- The comparison between RT-PCR and CellSearch™ method will be the positivity sample rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patient with head and neck squamous cell cancer stage III or IV histologically proven * Patient naive to any prior therapy * Patient with operate cancer and resectable tumor * Hemoglobin ≥ 10g / dL * Performance status ≤ 2 * Ability to provide written informed consent * Patient's legal capacity to consent to study participation Exclusion Criteria: * Other previous histology tumors * Medical conditions or acute or chronic severe psychiatric disorders * Deprived of liberty or under supervision
References
Publications (0)
Data not yet available
No reference posted for this study.